Danielle Valletti, Assistant Editor

Tabitha Peterson, PharmD, discusses how teamwork, strategy, and antidoping expertise sharpen patient care and athlete safety.

Ruxolitinib can shape myelofibrosis care, and other drugs' dosing, resistance, and next-generation combinations are under study.

Data from a phase 2 response-adapted trial identify CD38 expression, plasma cell phenotype, and immune microenvironment as critical determinants of single-agent daratumumab efficacy.

Andrew Shao, PhD, senior vice president for global regulatory and scientific affairs at Niagen Bioscience, discusses how increased consumer access to information has shifted the supplement landscape toward greater demand for clinically validated products and transparency. He highlights the critical role pharmacists play in guiding consumers toward evidence-based supplements, while emphasizing the need for stronger regulatory enforcement and industry accountability to improve trust and product quality.

Ipsen discontinues tazemetostat after SYMPHONY-1 safety signals; pharmacists and FDA guide next steps for EZH2-mutant follicular lymphoma patients.

Niagen Bioscience’s NAD research, patents, and clinical trials, plus pharmacist-led supplement education to help consumers choose evidence-based vitamins and supplements.

The FDA approves Bristol Myers Squibb’s deucravacitinib (Sotyktu), a first oral tyrosine kinase 2 inhibitor for active psoriatic arthritis.

Explore how limited FDA enforcement impacts vitamins and supplements, as pharmacists push industry transparency with independent testing, COAs, and research-backed quality.

Circulating tumor cells detected in peripheral blood may serve as a powerful prognostic biomarker in newly diagnosed multiple myeloma.

Pembrolizumab neoadjuvant immunotherapy hits approximately 70% complete responses in desmoplastic melanoma.

A Baptist Health pharmacy expert shares real-world myelofibrosis oncology tips on JAK selection, symptom control, and navigating specialty drug costs.

Consumers seek clinically validated supplements as health information spreads quickly; Niagen Bioscience stresses independent evidence, and pharmacists guide choices using trusted certifications.

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, FASTCT, discusses the importance of advocacy for oncology pharmacists in both patient care and professional recognition. She highlights practical ways pharmacists can advocate—such as refining an elevator pitch, participating in virtual Hill Days, and partnering with professional organizations such as ASHP and HOPA.

Long-term care pharmacies optimize medication, vaccines, and safer therapies to boost patient care, cut risks, and navigate Medicare barriers.

Neoadjuvant pembrolizumab reshapes desmoplastic melanoma care, spotlighting sequence integrity, pharmacist-led toxicity readiness, and oncology networks accelerating rare-cancer immunotherapy innovation.

Oral bacteria such as Fusobacterium nucleatum may fuel breast cancer. Here's what pharmacists should know about periodontal health and genetic risk.

Artificial intelligence helps hematology teams and pharmacists distinguish prefibrotic myelofibrosis from essential thrombocythemia, improving the accuracy of myeloproliferative neoplasm diagnosis and oncology care.

Explore PREVENT Risk Equations reshaping hypertension care, HFpEF therapy, and CKD-related hyperkalemia.

Carfilzomib may boost BCMA CAR T-cell therapy after relapse in multiple myeloma, guiding oncology pharmacists on safer immunotherapy sequencing.

The oral solution improves central diabetes insipidus dosing precision, helping pharmacy teams tailor therapy, counsel patients, and monitor hyponatremia.

Oncology pharmacists can advocate and communicate clearly to boost recognition, strengthen care teams, and improve cancer treatment outcomes.

HER2 breast cancer vaccine boosted by CD27 sparked durable CD4 memory and dramatic tumor regression in studies.

FDA clears oral Wegovy pills for weight loss, while Lemme Burn Gummies tout metabolic support; plus new thalassemia anemia drug and Lucentis biosimilar.

Oncology pharmacists can share advocacy tips, craft elevator pitches, and use virtual Capitol Hill days to boost patient access and cancer care.

Circulating tumor cell PD-L1 liquid biopsy guides PD-1 therapy in lung cancer, helping oncology pharmacists predict response and monitor disease in real time.

Experts discuss the importance of optimizing immunotherapy for advanced NSCLC, enhancing treatment selection and patient care.

Tagraxofusp monotherapy in myelofibrosis shows symptom relief with manageable toxicity, as pharmacists can monitor capillary leak syndrome and cytopenias.

Neurology CPAs let pharmacists speed multiple sclerosis therapy, order labs and meds, cut delays, boost adherence, and expand collaborative care.

FDA accepts Iberdomide new drug application for relapsed or refractory multiple myeloma; pharmacists prepare for oral anti-CD38 combos, MRD-driven care.